Mail

UK markets closed

FTSE 100
8,139.83
+60.97(+0.75%)
FTSE 250
19,824.16
+222.18(+1.13%)
AIM
755.28
+2.16(+0.29%)
GBP/EUR
1.1671
+0.0014(+0.12%)
GBP/USD
1.2494
-0.0017(-0.13%)
Bitcoin GBP
51,152.30
-602.57(-1.16%)

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Amneal Pharmaceuticals, Inc. (AMRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Add to watchlist

5.93

+0.03

(+0.42%)

As of 03:23PM EDT. Market open.

Currency in USD

Valuation measures⁴

Market cap (intra-day)	1.82B
Enterprise value	4.48B
Trailing P/E	N/A
Forward P/E	N/A
PEG ratio (5-yr expected)	N/A
Price/sales (ttm)	0.43
Price/book (mrq)	92.03
Enterprise value/revenue	1.87
Enterprise value/EBITDA	11.21

Trading information

Stock price history

Beta (5Y monthly)	1.35
52-week change ³	205.70%
S&P500 52-week change ³	21.08%
52-week high ³	6.46
52-week low ³	1.74
50-day moving average ³	5.71
200-day moving average ³	4.75

Share statistics

Avg vol (3-month) ³	1.59M
Avg vol (10-day) ³	1.74M
Shares outstanding ⁵	308.55M
Implied shares outstanding ⁶	316.4M
Float ⁸	135.69M
% held by insiders ¹	55.79%
% held by institutions ¹	29.16%
Shares short (15 Apr 2024) ⁴	2.8M
Short ratio (15 Apr 2024) ⁴	1.58
Short % of float (15 Apr 2024) ⁴	1.09%
Short % of shares outstanding (15 Apr 2024) ⁴	0.91%
Shares short (prior month 15 Mar 2024) ⁴	2.07M

Dividends & splits

Forward annual dividend rate ⁴	N/A
Forward annual dividend yield ⁴	N/A
Trailing annual dividend rate ³	0.00
Trailing annual dividend yield ³	0.00%
5-year average dividend yield ⁴	N/A
Payout ratio ⁴	0.00%
Dividend date ³	N/A
Ex-dividend date ⁴	N/A
Last split factor ²	N/A
Last split date ³	N/A

Financial highlights

Fiscal year

Fiscal year ends	31 Dec 2023
Most-recent quarter (mrq)	31 Dec 2023

Profitability

Profit margin	-3.51%
Operating margin (ttm)	13.19%

Management effectiveness

Return on assets (ttm)	4.66%
Return on equity (ttm)	-36.06%

Income statement

Revenue (ttm)	2.39B
Revenue per share (ttm)	13.59
Quarterly revenue growth (yoy)	1.20%
Gross profit (ttm)	N/A
EBITDA	500.78M
Net income avi to common (ttm)	-83.99M
Diluted EPS (ttm)	-0.48
Quarterly earnings growth (yoy)	N/A

Balance sheet

Total cash (mrq)	93.74M
Total cash per share (mrq)	0.31
Total debt (mrq)	2.75B
Total debt/equity (mrq)	4,486.69%
Current ratio (mrq)	1.63
Book value per share (mrq)	0.06

Cash flow statement

Operating cash flow (ttm)	345.58M
Levered free cash flow (ttm)	303.9M